Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

PHASE2TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 21, 2022

Primary Completion Date

July 23, 2025

Study Completion Date

July 23, 2025

Conditions
Small-cell Lung CancerNeuroendocrine Carcinoma
Interventions
DRUG

Iadademstat

Patients will be treated with iadademstat given at a dose of 150 microgram PO administered on a 5 day on-2 day off schedule every week (days 1 through 21)

DRUG

Paclitaxel

Patients will be treated with Paclitaxel given at a dose of 80 mg/m2 intravenous administration weekly day 1, 8 and 15 (days 1 through 21).

Trial Locations (3)

14263

Roswell Park Cancer Institute, Buffalo

19111

Fox Chase Cancer Center, Philadelphia

84112

Huntsman Cancer Institute, Salt Lake City

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Oryzon Genomics S.A.

INDUSTRY

lead

Fox Chase Cancer Center

OTHER

NCT05420636 - Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET | Biotech Hunter | Biotech Hunter